Protein panels

Multiplexed protein panels

We perform multiplexed protein panel analysis using Luminex xMAP® technology covering more than 600 proteins in humans and other species. This technology allows us to study biomarkers of cancer, cardiovascular diseases, immunology, neurology, metabolism and endocrinology, etc. in samples of serum, plasma, urine, extravascular fluids, biopsies and cell cultures, among others.

 

We offer our customers a wide range of panels that can be configured according to the particular needs of their line of research.

A comprehensive study of biomarkers in cancer

We quantify dozens of proteins involved in different stages of tumourogenesis through configurable panels, providing highly relevant information to understand their origin and development:

BTLA, CD27, CD28, CD40, CD80/B7-1, CD86/B7-2, CTLA-4/CD152, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, PD-L2, TIM-3,TLR-2, 4-1BBL/TNFSF9, 5’-NT/CD73, APRIL, Arginase-1, B7-H2/ICOSL, B7-H3/CD276, B7-H4/VTCN1, B7-H5/VISTA, B7-H6, BAFF/BLyS, CD25/IL-2Rα, CD30/TNFRSF8, CD40L, CD137/4-1BB, CD226/DNAM-1, E-Cadherin, FGL1/Hepassocin, Galectin-1, Galectin-3, Granulysin, Granzyme B, IDO1, MICA, MICB, Nectin-2, Nectin-4, OX40/CD134, Perforin, PVR/CD155, Siglec-7 y Siglec-9.

α-Fetoprotein (AFP), CA125, CA15-3, CA19-9, CEA, CYFRA21-1, sFAS/TNFRSF6, sFasL, FGF-2/FGF-basic, HCGβ, HE4, HGF, IL-6, IL-8/CXCL8, Leptin, MIF, Osteopontin (OPN), Prolactin, SCF, TGFα, TNFα, TRAIL/TNFSF10, VEGF-A.

Angiopoietin-2, Angiostatin, BMP-9, EGF, Endoglin, Endothelin-1, FGF-1/FGF-acidic, FGF-2/FGF-basic Follistatin (FST), G-CSF, HB-EGF, HGF, IL-8/CXCL8, Leptin, Placental Growth Factor (PLGF), VEGF-A, VEGF-C, VEGF-D, sAXL, sCD31/sPECAM-1, sc-Kit/sStem Cell Factor Receptor (SCFR), sE-Selectin, sEGFR/sHER1/sErbB1, sHER2/sEGFR2/sErbB2, sHER3/sEGFR3/sErbB3, sHGFR/sc-Met, sIL-6Rα, sNeuropilin-1 (sNRP-1), Osteopontin (OPN), PDGF-AB/BB, Tenascin-C (TN-C), Thrombospondin-2 (TSP-2), sTIE-2, suPAR, sVEGFR1/sFlt-1, sVEGFR2/sKDR/sFlk-1 y sVEGFR3/sFlt-4.

DKK1, GDF15, Neuron-specific Enolase, Osteonectin/SPARC, Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK y YKL40/CHI3L1.

A comprehensive study of biomarkers in cancer

We quantify dozens of proteins involved in different stages of tumourogenesis through configurable panels, providing highly relevant information to understand their origin and development:

BTLA, CD27, CD28, CD40, CD80/B7-1, CD86/B7-2, CTLA-4/CD152, GITR, GITRL, HVEM, ICOS, LAG-3, PD-1, PD-L1, PD-L2, TIM-3,TLR-2,

4-1BBL/TNFSF9, 5’-NT/CD73, APRIL, Arginase-1, B7-H2/ICOSL, B7-H3/CD276, B7-H4/VTCN1, B7-H5/VISTA, B7-H6, BAFF/BLyS, CD25/IL-2Rα, CD30/TNFRSF8, CD40L, CD137/4-1BB, CD226/DNAM-1, E-Cadherin, FGL1/Hepassocin, Galectin-1, Galectin-3, Granulysin, Granzyme B, IDO1, MICA, MICB, Nectin-2, Nectin-4, OX40/CD134, Perforin, PVR/CD155, Siglec-7 y Siglec-9.

α-Fetoprotein (AFP), CA125, CA15-3, CA19-9, CEA, CYFRA21-1, sFAS/TNFRSF6, sFasL, FGF-2/FGF-basic, HCGβ, HE4, HGF, IL-6, IL-8/CXCL8, Leptin, MIF, Osteopontin (OPN), Prolactin, SCF, TGFα, TNFα, TRAIL/TNFSF10, VEGF-A.

Angiopoietin-2, Angiostatin, BMP-9, EGF, Endoglin, Endothelin-1, FGF-1/FGF-acidic, FGF-2/FGF-basic Follistatin (FST), G-CSF, HB-EGF, HGF, IL-8/CXCL8, Leptin, Placental Growth Factor (PLGF), VEGF-A, VEGF-C, VEGF-D, sAXL, sCD31/sPECAM-1, sc-Kit/sStem Cell Factor Receptor (SCFR), sE-Selectin, sEGFR/sHER1/sErbB1, sHER2/sEGFR2/sErbB2, sHER3/sEGFR3/sErbB3, sHGFR/sc-Met, sIL-6Rα, sNeuropilin-1 (sNRP-1), Osteopontin (OPN), PDGF-AB/BB, Tenascin-C (TN-C), Thrombospondin-2 (TSP-2), sTIE-2, suPAR, sVEGFR1/sFlt-1, sVEGFR2/sKDR/sFlk-1 y sVEGFR3/sFlt-4.

DKK1, GDF15, Neuron-specific Enolase, Osteonectin/SPARC, Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK y YKL40/CHI3L1.

Immune response to the SARS-CoV-2 virus

With xMAP® technology we can quantify the levels of IgG, IgM and IgA antibodies to four antigens of SARS-CoV-2 in serum and plasma samples:

 

  • Protein S (S1 subunit)
  • Protein S (S2 subunit)
  • RBD domain
  • N protein

We can also study in depth the response of the patients’ immune system and the cytokine storm phenomenon through different configurable panels that include a variable number of cytokines, as well as the coagulopathies associated with this phenomenon.

Immune response to the SARS-CoV-2 virus

With xMAP® technology we can quantify the levels of IgG, IgM and IgA antibodies to four antigens of SARS-CoV-2 in serum and plasma samples:

 

  • Protein S (S1 subunit)
  • Protein S (S2 subunit)
  • RBD domain
  • N protein

We can also study in depth the response of the patients’ immune system and the cytokine storm phenomenon through different configurable panels that include a variable number of cytokines, as well as the coagulopathies associated with this phenomenon.

Immune response to the SARS-CoV-2 virus

With xMAP® technology we can quantify the levels of IgG, IgM and IgA antibodies to four antigens of SARS-CoV-2 in serum and plasma samples:

 

  • Protein S (S1 subunit)
  • Protein S (S2 subunit)
  • RBD domain
  • N protein

We can also study in depth the response of the patients’ immune system and the cytokine storm phenomenon through different configurable panels that include a variable number of cytokines, as well as the coagulopathies associated with this phenomenon.

Differential expression studies at gene and protein level

We study differential expression at the gene level of pre-configured panels of candidate genes by quantifying mRNAs using branched DNA (bDNA) technology.

 

RNA biomarkers can be effective indicators of biological processes, pathological processes or possible responses to treatment. Therefore, this technology is especially interesting as a complement to the study of RNA by NGS, when a targeted quantification of RNA biomarkers is desired, and in combination with protein panels, to jointly obtain information about differential expression at the gene and protein level.

White Paper

Por favor, rellena este formulario y te enviaremos el White Paper elegido a tu bandeja de correo.




* Campo obligatorio.

** Al hacer click en "Enviar a mi email" declaro que he leído y acepto la Política de Privacidad y acepto recibir comunicaciones comerciales en el futuro.

Todos los campos deben estar cumplimentados y el email debe tener un formato correcto.